Erasca announced that Shannon Morris, M.D., Ph.D., previously senior vice president of clinical development of Erasca, has been promoted to chief medical officer, and Chandra Lovejoy, M.S., previously senior vice president of regulatory affairs of Erasca, has been promoted to chief regulatory affairs officer, effective immediately. Dr. Morris succeeds Wei Lin, M.D., who is stepping down to pursue other opportunities.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on ERAS:
- Erasca Strengthens Clinical and Regulatory Leadership with Two Key Appointments as Company Transitions to Late-Stage Development
- Erasca initiated with a Buy at Mizuho
- Erasca reports Q4 EPS ($1.06) vs. (26c) last year
- Erasca Reports Fourth Quarter 2022 and Full Year 2022 Financial Results and Business Updates
- Erasca Announces Poster Presentation at the 2023 AACR Annual Meeting
